## **Toward a Total Synthesis of Peloruside A: Enantioselective Preparation of the C8**−**C19 Region**

**LETTERS 2003 Vol. 5, No. 26 <sup>4959</sup>**-**<sup>4961</sup>**

**ORGANIC**

## **Richard E. Taylor\* and Meizhong Jin**

*Department of Chemistry and Biochemistry and the Walther Cancer Research Center, University of Notre Dame, 251 Nieuwland Science Hall, Notre Dame, Indiana 46556-5670*

*taylor.61@nd.edu*

**Received September 26, 2003**

## **ABSTRACT**



**An efficient synthetic sequence toward the C8**−**C19 region of peloruside A has been developed. The route is highlighted by a selective electrophilic cyclization reaction, a single-step epoxide ring-opening/methylation sequence, and a stereoselective Mukaiyama aldol reaction.**

Peloruside A is a cytotoxic macrolide isolated from a New Zealand sponge, *Mycale hentschi*. <sup>1</sup> The structure was originally determined by extensive NMR solution studies. More recently, Miller and co-workers reported a study that established peloruside A as a potent cytotoxic agent with epothilone-like microtubule-stabilizing activity.<sup>2</sup> This report noted interesting structural similarities between the two biologically related polyketides peloruside A and the epothilones (i.e., contiguous hydroxyl, *gem*-dimethyl, carbonyl; C11-C9 peloruside, C3-C5 epothilone). This proposal implied that the C15-stereogenic center of peloruside A was of opposite configuration to the corresponding center in epothilone. More recently, the absolute stereochemistry of natural peloruside A was unambiguously determined to have the identical C15 stereochemistry as epothilone by the De Brabander group through an elegant total synthesis effort.3,4

Our previous experience with the conformation-activity relationships of epothilone<sup>5</sup> revealed interesting shape and size similarities to peloruside A, and a comparison is shown in Figure 1. Although there is no direct experimental evidence, peloruside A and the epothilones may have



**Figure 1.** Structural and conformational comparison of peloruside A and epothilone B derived from NMR and computer modeling analysis.

<sup>(1)</sup> West, L. M.; Northcote, P. T. *J. Org. Chem.* **2000**, *65*, 445. (2) Hood, K. A.; West, L. M.; Rouwe, B.; Northcote, P. T.; Berridge, M. V.; Wakefield, S. J.; Miller, J. H. *Cancer Res.* **2002**, *62*, 3356.

overlapping pharmacophores. Toward our interest in the structural and conformational constraints of peloruside's biological activity, we have begun a program where total synthesis is an initial goal. Herein we report our preliminary efforts toward that aim.

The synthesis commenced with readily available oxazolidinone **1** (Scheme 1), which was stereoselectively alkylated



with BOMCl in the presence of titanium tetrachloride.<sup>6</sup> After an exchange of protecting groups, the chiral auxiliary was reductively removed with LiBH4. Oxidation of **<sup>2</sup>** with Dess-Martin periodinane<sup>7</sup> followed by a Still-Gennari olefination<sup>8</sup> provided exclusively the (*Z*)-trisubstituted alkene **3**. Then, a two-step conversion of the methyl ester to the corresponding aldehyde allowed for a Brown asymmetric allylation to set the C15 stereogenic center and provide  $4$  (dr = 97:3, 77%) for two steps).

The nonpolar physical properties of alcohol **4** made purification difficult, a common problem with this allylation method due to reaction byproducts. However, a diastereorandom allylation with inexpensive allylmagnesium bromide followed by chromatographic separation and processing of the undesired  $4-15R$  isomer through Mitsunobu inversion<sup>9</sup> proved to be a practical alternative for large-scale work. As shown in Scheme 2, simple Grignard allylation proceeded in good yield to provide a 1:1 mixture of diastereomers that were easily separable by column chromatography. The twostep conversion of the undesired isomer proceeded efficiently to provide diastereomerically pure **4**-15*S*. The 16,17-(*Z*) olefin geometry was maintained through this sequence as proven by NOE studies (see Supporting Information).



<sup>(4)</sup> For additional synthetic efforts towards peloruside A, see: (a) Paterson, I.; Di Francesco, M. E.; Kuhn, T. *Org. Lett.* **2003**, *5*, 599. (b) Ghosh, A. K.; Kim, J.-H. *Tetrahedron Lett.* **2003**, *44*, 3967. (c) Hoye, T. R.; Hu, M. 38th National Organic Chemistry Symposium, Bloomington, IN, June 8-12, 2003; Abstract A22. (d) Ghosh, A. K.; Kim, J.-H. *Tetrahedron Lett.* **2003**, *44*, 7659.

(8) Still, W. C.; Gennari, C. *Tetrahedron Lett.* **1983**, *24*, 4405.

```
(9) Mitsunobu, O. Synthesis 1981, 1.
```


The next stage of the plan was to build the 1,3-syn relationship between C13 and C15. Iodine-induced carbonate cyclization methodology originally published by Bartlett<sup>10a</sup> and later improved by Smith<sup>10b</sup> was first considered, Scheme 3. This is a particularly interesting substrate for this elec-



trophilic cyclization reaction because of the presence of two potential sites for reactivity. One could envision electrophilic activation of the more electron-rich trisubstituted olefin to provide a five-membered cyclic carbonate<sup>11</sup> or the sterically accessible terminal olefin to provide the desired sixmembered cyclic carbonate. In fact, treatment of the mixed carbonate with either  $I_2$  or IBr, at low temperature, provided complex mixtures of products. However, the use of *N*iodosuccinimide proved to be selective for the formation of a single compound, carbonate **7**, in 92% yield. As expected, this material, upon exposure to basic methanol solution and protection, efficiently provided the *syn*-epoxy ether **8**. Generation of the polyacetate *syn*-diol would then be unveiled by epoxide ring opening with an acyl anion synthon.

The lithium anion of dithiane was used to fragment the epoxide and proceeded in 85% yield as shown in Scheme 3. Formation of C13-methyl ether was accomplished with

<sup>(5) (</sup>a) Yoshimura, F.; Rivkin, A.; Gabarda, A. E.; Chou, T.-C.; Dong, H.; Sukenick, G.; Morel, F. F.; Taylor, R. E.; Danishefsky, S. J. *Angew. Chem.*, *Int. Ed.* **2003**, *42*, 2518. (b) Taylor, R. E.; Chen, Y.; Beatty, A.; Myles, D. C.; Zhou, Y. *J. Am. Chem. Soc*. **2003**, *125*, 26. (c) Taylor, R. E.; Zajicek, J. *J. Org. Chem.* **1999**, *64*, 7224.

<sup>(6)</sup> Ihara, M.; Katsumata, A.; Setsu, F.; Tokunaga, Y.; Fukumoto, K. *J. Org. Chem.* **1996**, *61*, 677.

<sup>(7)</sup> Dess, D. B.; Martin, J. C. *J. Org. Chem.* **1983**, *48*, 4155.

<sup>(10) (</sup>a) Bartlett, P. A.; Meadows, J. D.; Brown, E. G.; Morimoto, A.; Jernstedt, K. K. *J. Org. Chem.* **<sup>1982</sup>**, *<sup>47</sup>*, 4013. (b) Duan, J. J-W.; Smith, A. B., III. *J. Org. Chem.* **1993**, *58*, 3703.

<sup>(11)</sup> Bongini, A.; Cardillo, G.; Orena, M.; Porzi, G.; Sandri, S. *J. Org. Chem.* **1982**, *47*, 4626.

methyl iodide in the presence of KOtBu in 78% yield. This was followed by hydrolysis of the dithiane to provide aldehyde **9**. A more efficient generation of the C13-methyl ether was accomplished by in situ alkylation of the intermediate alkoxide resulting from epoxide ring opening. As shown in Scheme 4, exposure of epoxide **8** to the lithiated



dithiane followed by the addition of an HMPA solution of dimethyl sulfate led to direct isolation of methyl ether **10** in 85% yield.

Mukaiyama aldol<sup>12</sup> reaction of the  $\beta$ -methoxy aldehyde **9** provided methyl ketone **11** in 91% yield as shown in Scheme 5. Mosher ester analysis<sup>13</sup> of the major isomer, obtained in an 8:1 mixture, proved to have the desired absolute stereochemistry at C11 and thus a 1,3-anti stereochemical relationship between C11 and C13.



In summary, we have developed an efficient, enantioselective route to a protected C8-C19 fragment of peloruside A. The route is highlighted by a selective electrophilic cyclization reaction, a single-step epoxide ring-opening/ methyl ether formation, and an anti stereoselective Mukaiyama aldol reaction. Conversion of this advanced intermediate to peloruside A and analogues is currently underway in our laboratories, and results along these lines will be reported in due course.

**Acknowledgment.** This work was partially supported by the National Cancer Institute and National Institutes of Health (CA84599). R.E.T. thanks Eli Lilly for a Grantee Award. This work was done in collaboration with the Walther Cancer Research Institute of Indianapolis, Indiana.

**Supporting Information Available:** Full experimental and characterization data for all new compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

OL0358814

<sup>(12) (</sup>a) Reetz, M. T.; Kesseler, K.; Jung, A. *Tetrahedron Lett.* **1984**, *25*, 729. (b) Trieselmann, T.; Hoffmann, R. W. *Org. Lett.* **2000**, *2*, 1209. (c) Evans, D. A.; Dart, M. J.; Duffy, J. L.; Yang, M. G. *J. Am. Chem. Soc.* **1996**, *118*, 4322. (d) Willson, T. M.; Kocrenski, P.; Jarowicki, K.; Isaac, K.; Hitchcock, P. M.; Faller, A.; Campbell, S. F. *Tetrahedron* **1990**, *46*, 1767.

<sup>(13)</sup> Dale, J. S.; Mosher, H. S. *J. Am. Chem. Soc*. **1973**, *95*, 512.